Cart
sales@molnova.com
CCG-143140
CAS No. 891016-02-7
CCG-143140( ML-SI3 )
Catalog No. M24914 CAS No. 891016-02-7
CCG-143140 is a GLP-1 receptor inverse agonists.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 71 | In Stock |
|
| 2MG | 40 | In Stock |
|
| 5MG | 64 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 235 | In Stock |
|
| 50MG | 365 | In Stock |
|
| 100MG | 548 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCCG-143140
-
NoteResearch use only, not for human use.
-
Brief DescriptionCCG-143140 is a GLP-1 receptor inverse agonists.
-
DescriptionCCG-143140 is a GLP-1 receptor inverse agonists.
-
In VitroML-SI3 (10 μM) inhibits ML-SA1-evoked Ca2+ signals in HeLa cells.ML-SI3 (25-75 μM, 24h) disrupts tegumental integrity of adult schistosomes.ML-SI3 (10 μM) blocks Rapamycin (HY-10219)-evoked ITRPML1 in mimic of lysosomal lumen.ML-SI3 (3 μM, 6 h) abolishes the increase in both LC3II and p62 levels induced by hypoxia/reoxygenation (H/R) (4 h H/2 h R) in neonatal rat ventricular myocytes (NRVM).
-
In VivoML-SI3 (1.5 mg/kg, i.p., four times) attenuates I/R injury in mouse cardiomyocytes. Animal Model:Myocardial Ischemia/reperfusion (I/R) injury miceDosage:1.5 mg/kg Administration:Intraperitoneal injection (i.p.), four times before and during the in vivo I/R (ischemia 30 min and reperfusion 1 day)Result:Restored the blocked autophagic fux in the cardiomyocytes subjected to I/R.
-
SynonymsML-SI3
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGLP-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number891016-02-7
-
Formula Weight429.58
-
Molecular FormulaC23H31N3O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (116.39 mM)
-
SMILESO=S(C1=CC=CC=C1)(NC2C(N3CCN(C4=CC=CC=C4OC)CC3)CCCC2)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
V-0219
V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.
-
Retatrutide
Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
-
PF-06882961
PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.
